| Aug 5 |
Lantern Pharma announces update from mid-stage trial for non-small cell lung cancer treatment
|
| Aug 5 |
Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort
|
| Aug 1 |
Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET
|
| Jul 15 |
We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate
|
| Jul 10 |
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
|
| Jun 12 |
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
|
| May 24 |
Lantern Pharma files for $150M mixed shelf offering
|
